. "Appendix K: Prospects for Immunizing Against Influenza Viruses A and B." New Vaccine Development: Establishing Priorities: Volume I, Diseases of Importance in the United States. Washington, DC: The National Academies Press, 1985.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
New Vaccine Development Establishing Priorities, Volume I: Diseases of Importance in the United States
Luscombe, F.A., A.S.Monto, and J.V.Baublis. 1980. Mortality due to Reye’s syndrome in Michigan; distribution and longitudinal trends. J. Infect. Dis. 142(3):363–371.
Maassab, H.F., T.Francis, F.M.Davenport, A.V.Hennessy, E.Minuse, and G.Anderson. 1969. Laboratory and clinical characteristics of attenuated strains of influenza virus. Bull. World Health Org. 41:589–594.
Mawson, J., and C.Swan. 1943. Intranasal vaccination of humans with living attenuated influenza virus strains. Med. J. Aust. 1:394–399.
Monto, A.S., and F.Kioumehr. 1975. The Tecumseh study of respiratory illness. IX. Occurrence of influenza in the community, 1966–1971. Am. J. Epidemiol. 102(6):553–563.
Office of Technology Assessment. 1981. Cost Effectiveness of Influenza Vaccination. Congress of the united States. Pub. No. OTA-H-152. Washington, B.C.: U.S. Government Printing Office.
Salk, J.E., H.E.Pearson, P.N.Brown, and T.F.Francis, Jr. 1944. Protective effect of vaccination against induced influenza B. Proc. Soc. Exper. Biol. Med. 55:106–107.
Seal, J.R. 1977. Clinical studies of influenza vaccines—1976. Introduction. J. Infect. Dis. 136(suppl.):S345-S346.
Sigel, M.M., A.W.Kitts, A.B.Light, and W.Henle. 1950. Recurrence of influenza A prime in a boarding school after 2 years. J. Immunol. 64:33–38.
Stuart-Harris, C. 1980. The present status of live influenza virus vaccine. J. Infect. Dis. 142(5):784–793.
Sullivan-Bolyai, J.Z., and L.Corey. 1981. Epidemiology of Reye syndrome. Epidemiol. Rev. 3:1–26.
